Granulocyte Antibodies, Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
The work-up of individuals having febrile, nonhemolytic transfusion reactions
The detection of individuals with autoimmune neutropenia
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Granulocyte Ab, S
Granulocyte Binding IgG
Granulocyte Binding IgG
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Container/Tube: Red top
Specimen Volume: 1.5 mL
Additional Information: Only pretransfusion reaction specimen is acceptable.
Forms: If not ordering electronically, submit a General Request Form (Supply T239) with the specimen.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross OK
Mild OK; Gross OK
Mild OK; Gross OK
Serum gel tube
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Serum Red||Refrigerated (preferred)||30 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Granulocyte antibodies are induced by pregnancy or prior transfusion and are associated with febrile, nonhemolytic transfusion reactions. Patients who have been immunized by previous transfusions, pregnancies, or allografts frequently experience febrile, nonhemolytic transfusion reactions which must be distinguished from hemolysis before further transfusions can be safely administered. Granulocyte antibodies may also be present in autoimmune neutropenia.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
A positive result in an individual being worked up for a febrile transfusion reaction indicates the need for leukocyte-poor (filtered) red blood cells.
This test cannot distinguish between allo- and autoantibodies
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Not useful for diagnosis of neutropenia caused by marrow suppression by drugs or tumors
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
Verheugt FW, von dem Borne AE, Decary F, Engelfreit CP: The detection of granulocyte alloantibodies with an indirect immunofluorescence test. Br J Haematol 1997;36:533-534
Method Description Describes how the test is performed and provides a method-specific reference
Purified granulocyte preparations from normal donors are incubated with patient's test serum and then with fluorescein-tagged antihuman globulin reagent. Sera containing the antibodies deposit immunoglobulin on the target cell membrane which is detected by the second stage antibody and visualized by fluorescence microscopy.(1)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday, Wednesday, Friday; 7:30 a.m.-5:00 p.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|LAGG||Granulocyte Ab, S||In Process|